The FDA has approved GlaxoSmithKline's shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised – a key step in the UK drugmaker's plan to build the shot into a £4 ...

If you've ever had chickenpox, you are at risk of developing shingles in the future. While people might assume that shingles — a painful, blistering rash — only affects older adults, 1 in 3 ...

A new study has found that U.S. adults over the age of 65 who received both doses of the recombinant zoster shingles vaccine (Shingrix) had a lower rate of dementia than others in the same age group.

Shingrix, the new shingles vaccine, is over 90 percent effective in preventing the painful viral infection Julie Mazziotta is the Senior Sports Editor at PEOPLE, covering everything from the NFL to ...

The recombinant zoster vaccine (Shingrix) is very effective against the viral rash, but research has found that it may also help prevent or treat dementia.

Add Yahoo as a preferred source to see more of our stories on Google. A shingles vaccine could delay the onset of dementia, according to a new study. Robert Michael/dpa The shingles vaccine given to ...

FDA expanded the approval of Shingrix, an adjuvanted recombinant zoster vaccine, for adults at increased risk of shingles due to immunosuppression, manufacturer GlaxoSmithKline (GSK) announced on ...

On the heels of approval of a better vaccine for the painful condition shingles, adults over 50 should plan to roll up their sleeves -- again. The new vaccine, Shingrix, will likely be recommended ...

There’s a new shingles vaccine and experts say you should get it if you’re over 50 — even if you’ve already been vaccinated. The new vaccine, called Shingrix, works far better to prevent the extremely ...

GlaxoSmithKline’s shingles vaccine Shingrix shot out of the gate after its 2017 launch and performed so well that the drugmaker eventually ran into supply shortages due to higher-than-expected demand.

After the rofecoxib (Vioxx) withdrawal in 2004 made painfully clear how much harm a passive reporting system can miss, ...

By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns that the British drugmaker's ...